🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,60 EUR

Máx. histórico

912,40

63 días

Caída desde máximo

-10,61%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,07%

Cierre anterior

815,00

Rango de hoy

812,40 – 835,80

Volumen hoy

109.168

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,82 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
998,93 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 19 horas
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
08/03/2016 10,06 10,44 10,05 10,15 -0,78% 3,88% 7.551
07/03/2016 10,15 10,23 10,06 10,23 +1,89% 1,67% 2.388
04/03/2016 10,33 10,33 10,04 10,04 -0,10% 2,81% 4.247
03/03/2016 10,03 10,11 10,02 10,05 -0,50% 0,90% 4.557
02/03/2016 10,53 10,54 10,05 10,10 -3,63% 4,65% 2.650
01/03/2016 10,11 10,50 10,11 10,48 +3,76% 3,86% 4.415
29/02/2016 10,01 10,40 10,01 10,10 -1,94% 3,90% 1.407
26/02/2016 10,45 10,45 10,00 10,30 -1,44% 4,31% 6.396
25/02/2016 10,48 10,55 10,20 10,45 -0,38% 3,34% 15.724
24/02/2016 10,53 10,61 10,49 10,49 -1,04% 1,14% 6.114
23/02/2016 10,62 10,62 10,60 10,60 -0,47% 0,19% 3.210
22/02/2016 10,79 10,79 10,60 10,65 -1,02% 1,76% 5.141
19/02/2016 10,52 10,77 10,52 10,76 +0,75% 2,38% 7.196
18/02/2016 10,62 10,78 10,62 10,68 +0,66% 1,51% 5.637
17/02/2016 10,59 10,61 10,46 10,61 +0,09% 1,42% 4.178
16/02/2016 10,42 10,60 10,42 10,60 +1,73% 1,73% 897
15/02/2016 10,32 10,64 10,32 10,42 +1,36% 3,10% 2.555
12/02/2016 10,22 10,40 10,20 10,28 +0,29% 1,96% 2.791
11/02/2016 10,30 10,63 10,25 10,25 -2,10% 3,69% 6.577
10/02/2016 10,22 10,64 10,22 10,47 +1,06% 4,11% 7.737
09/02/2016 10,52 10,59 10,30 10,36 -1,80% 2,76% 18.702
08/02/2016 11,00 11,00 10,55 10,55 -4,09% 4,09% 14.007
05/02/2016 11,25 11,25 11,00 11,00 -0,09% 2,22% 9.404
04/02/2016 10,95 11,25 10,95 11,01 +1,01% 2,74% 2.762
03/02/2016 10,90 11,25 10,90 10,90 +0,00% 3,21% 7.947
02/02/2016 10,82 11,10 10,80 10,90 +0,74% 2,77% 4.300
01/02/2016 11,05 11,05 10,80 10,82 -2,61% 2,26% 2.266
29/01/2016 11,17 11,17 10,75 11,11 +0,45% 3,76% 1.373
28/01/2016 11,19 11,19 10,60 11,06 +0,09% 5,27% 10.851
27/01/2016 11,26 11,26 11,02 11,05 +0,45% 2,13% 406